PMID- 29246005
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220314
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 59
DP  - 2017 Nov 21
TI  - Potassium measurements and risk of type 2 diabetes: a dose-response meta-analysis 
      of prospective cohort studies.
PG  - 100603-100613
LID - 10.18632/oncotarget.21823 [doi]
AB  - OBJECTIVE: To clarify the relationship between serum, dietary, and urinary 
      potassium and the risk of type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS: 
      We searched PubMed and EMBASE through January 6, 2017 for studies reporting risk 
      estimates on the association of potassium measurements and the risk of T2DM. The 
      summary risk estimates were obtained through a random-effects model. 
      Dose-response analysis was conducted. RESULTS: Eight studies involving 5,053 
      cases and 119,993 individuals were included. A trend toward significance was 
      found in the highest versus lowest meta-analysis on serum potassium and T2DM risk 
      (RR = 0.79; 95% CI 0.60-1.04); moreover, the RR per 1 mmol/L increase in serum 
      potassium was 0.83 (95% CI 0.73-0.95). A non-significant association of dietary 
      potassium and T2DM risk was detected (RR for the highest versus lowest category: 
      0.93; 95% CI 0.81-1.06; RR for every 1000mg increase per day: 1.00, 95% CI 
      0.96-1.05). A similar non-significant association was found for urinary potassium 
      and T2DM risk (RR for the highest versus lowest category: 0.83; 95% CI 0.39-1.75; 
      RR per 10 mmol increase: 1.00; 95% CI 0.95-1.05). Evidence of a linear 
      association between serum, dietary, and urinary potassium and the risk of T2DM 
      was found (all P(non-linearity) > 0.05). CONCLUSIONS: Low serum potassium 
      increases the risk of T2DM in a linear dose-response manner; nevertheless, 
      neither dietary potassium nor urinary potassium shows any association with the 
      risk of T2DM. However, these findings should be interpreted with caution due to 
      limited studies.
FAU - Peng, Yang
AU  - Peng Y
AD  - Department of Endocrinology, The Second Affiliated Hospital, Chongqing Medical 
      University and Chongqing Clinical Research Center for Geriatrics, Chongqing, 
      China.
FAU - Zhong, Guo-Chao
AU  - Zhong GC
AD  - Department of Hepatobiliary Surgery, The Second Affiliated Hospital, Chongqing 
      Medical University, Chongqing, China.
FAU - Mi, Qiao
AU  - Mi Q
AD  - Department of Endocrinology, The Second Affiliated Hospital, Chongqing Medical 
      University and Chongqing Clinical Research Center for Geriatrics, Chongqing, 
      China.
FAU - Li, Kejia
AU  - Li K
AD  - Department of Endocrinology, The Second Affiliated Hospital, Chongqing Medical 
      University and Chongqing Clinical Research Center for Geriatrics, Chongqing, 
      China.
FAU - Wang, Ao
AU  - Wang A
AD  - Department of Endocrinology, The Second Affiliated Hospital, Chongqing Medical 
      University and Chongqing Clinical Research Center for Geriatrics, Chongqing, 
      China.
FAU - Li, Ling
AU  - Li L
AD  - Key Laboratory of Diagnostic Medicine (Ministry of Education) and Department of 
      Clinical Biochemistry, College of Laboratory Medicine, Chongqing Medical 
      University, Chongqing, China.
FAU - Liu, Hua
AU  - Liu H
AD  - Department of Pediatrics, University of Mississippi Medical Center, Jackson, 
      Mississippi, USA.
FAU - Yang, Gangyi
AU  - Yang G
AD  - Department of Endocrinology, The Second Affiliated Hospital, Chongqing Medical 
      University and Chongqing Clinical Research Center for Geriatrics, Chongqing, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20171011
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5725047
OTO - NOTNLM
OT  - dose-response
OT  - meta-analysis
OT  - potassium
OT  - systematic review
OT  - type 2 diabetes mellitus
COIS- CONFLICTS OF INTEREST The authors declare no competing financial interests.
EDAT- 2017/12/17 06:00
MHDA- 2017/12/17 06:01
PMCR- 2017/11/21
CRDT- 2017/12/17 06:00
PHST- 2017/07/28 00:00 [received]
PHST- 2017/09/23 00:00 [accepted]
PHST- 2017/12/17 06:00 [entrez]
PHST- 2017/12/17 06:00 [pubmed]
PHST- 2017/12/17 06:01 [medline]
PHST- 2017/11/21 00:00 [pmc-release]
AID - 21823 [pii]
AID - 10.18632/oncotarget.21823 [doi]
PST - epublish
SO  - Oncotarget. 2017 Oct 11;8(59):100603-100613. doi: 10.18632/oncotarget.21823. 
      eCollection 2017 Nov 21.